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 INTRODUCTION: 
 Psoriasis is a multisystem disease of unknown origin and is universal in 
occurrence. The most characteristic lesions consist of scaly, erythematous and 
sharply demarcated plaques present particularly over the extensor surfaces.1 Its 
prevalence in different population varies from 0% to 11.8%. In India it varies from 
0.44 to 2.8%. It is twice more common in men when compared to women. Psoriasis 
may begin at any age but more common to appear between 15 and 30 
years.2Depending upon HLA association, Henseler and Christophers had proposed 
two forms of psoriasis- type I with age of onset before 40 years and HLA 
associated, and type II with age of onset after 40years and lacking HLA 
association.3 
 Psoriasis has a genetic basis and is characterized by complex alterations in 
epidermal growth and differentiation together with multiple biochemical, vascular 
and immunological changes and also has some relation with nervous system. Based 
upon population studies, the estimated risk of psoriasis in an offspring is 41% if 
both parents are affected, 14% if single parent is affected and 2% if parent or 
sibling is not affected.4 
 Psoriasis is a chronic T – cell mediated inflammatory skin disease with a 
prevalence of 2%. The improvement of symptoms on treatment with ciclosporin 
was the first indication that it is T – cell mediated. Studies have also demonstrated 
that the infiltrates in psoriatic plaques are composed of Th1 cells and they are 
producing Th1 cytokines (example – TNF α). The improvement of psoriasis with 
 anti – THF therapies supported that psoriasis is a T cell type 1 or Th – 1 mediated 
disease. More recently Th 17 lymphocytes expressing IL-17 and Th 17 cytokines 
were found in psoriatic lesions, indicating that these cells are also involved in 
pathogenesis of psoriasis.5 
 Changes in skin may signal more serious health issues and they frequently 
serve as a marker for internal diseases. Insulin plays a central role in metabolic 
system and has an important role in maintaining homeostasis and physiology of the 
skin. In healthy persons, insulin regulates the balance between differentiation and 
proliferation of keratinocytes and form the equilibrium needed for the formation of 
epidermal structure. Insulin Resistance (IR) is defined as the inability of a known 
quantity of insulin to increase the glucose uptake and utilization of cells in an 
individual as it does in a normal population. In chronic inflammatory conditions 
like psoriasis, high levels of proinflammatory cytokines induce IR leading to an 
increased proliferation of basal keratinocytes and, at the same time deny access to 
differentiation.6 
The chronic inflammatory nature in psoriasis is thought to predispose the 
patients to other diseases with inflammatory component, of which the most notable 
are cardiovascular and metabolic disorders. This concept is supported with studies 
that show psoriasis in association with cardiovascular risk factors like diabetes, 
obesity, hypertension and dyslipidemia. The patients with severe psoriasis have 
high rate of obesity and diabetes than patients with mild psoriasis.7 
 The mechanisms for this association is uncertain, but proinflammatory 
cytokines like tumour necrosis-α have been demonstrated to decrease the activity of 
insulin, thus contributing to IR. Therefore inflammation is not only found in 
association with obesity but also with IR even when there is no increase in total 
body fat.8 
Associations between psoriasis and metabolic diseases have been 
increasingly recognized. Various epidemiological studies are establishing these 
association and they are determining the directionality of these associations and 
bringing the role of psoriasis as an independent risk factor for all these outcomes.9 
However there are many unanswered questions concerning the link between 
psoriasis and metabolic derangements. There is a scarcity of studies on the natural 
spectrum of psoriasis and screening procedures for MS in psoriasis patients.10 On 
the basis of the present knowledge, new guidelines are issued aiming to actively 
identify metabolic disease and other cardiovascular risk factors in psoriasis patients 
so that these factors are properly addressed.11 
 
 
 
 
 
 
 
 
  
AIMS AND OBJECTIVES: 
1. To estimate the level of insulin resistance in psoriasis patients. 
2. To study the other associated biochemical parameters like fasting plasma 
glucose, serum high density lipoproteins and serum triglycerides in 
psoriasis patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 REVIEW OF LITERATURE: 
General facts on psoriasis: 
Today, psoriasis is one of the most common inflammatory skin diseases 
disturbing the Caucasian population worldwide. Psoriasis is a persistent, immune-
mediated, inflammatory and proliferative skin disease with 2 to 4% occurrences of 
new cases in the general population. 
 Psoriasis vulgaris is the most common form. The clinical features of 
psoriasis vulgaris patients are erythematous-squamous lesions seen mainly on the 
extensor areas of elbows, knees and scalp. The lesions may remain stable for a long 
duration or become more intense spreading to the whole body surface area. 
Psoriasis can be categorized in terms of body surface area as mild, moderate and 
severe forms when 2%, 2-10% and over 10% respectively of body surface area 
were affected. 
Psoriasis can be classified into type I characterized by an onset before 40 
years with a positive family history and associated with HLA- Cw6, HLA- DR7; 
late onset type II with an onset after 40 years of age, having a negative family 
history and not associated with HLA. Psoriasis shows a multifactorial and 
polygenic pattern associated with genetic variations. There are several factors that 
contribute to exacerbation of disease such as stress, smoking, infections and 
medications like beta blockers, anti-inflammatory drugs. But the etiopathogenesis 
of psoriasis is not yet completely elucidated.12 
 
 Prevalence of psoriasis: 
The general prevalence of psoriasis in India was ranging from 0.44 to 
2.8%and the point prevalence of psoriasis is 8% .The male: female ratio was 1.1:1. 
Highest prevalence was found in 21-30 and 41 -50 age groups each forming 25%. 
Chronic plaque psoriasis is the most common clinical type (50%). The commonly 
involved sites were the palms and soles followed by scalp. Bedi had reported a 
family history of psoriasis in 14% of his patients.13 
A hospital based cross sectional study done at the department of 
Dermatology, have found 2.4% incidence of psoriasis on the basis of characteristic 
clinical features such as presence of scaly patches with silvery scales. This study 
included various types of psoriasis like palmoplantar, scalp, pustular, flexural, nail 
and erythrodermic psoriasis. This incidence corresponds with 2.3% incidence of a 
North Indian study at a tertiary health care hospital. Okhandiar et al., had found an 
incidence of 0.44 to 2.2% among total skin patients in his comprehensive study. 14 
Etiopathogenesis of psoriasis: 
Psoriasis is a T lymphocyte based disease identified by the characteristic 
appearance of raised, red scaly skin lesions. The major pathological changes in 
these lesions are epidermal hyperproliferation together with abnormal 
differentiation, angiogenesis, vascular proliferation and inflammatory infiltration in 
the dermis. This epidermal hyperplasia and inflammation are responsible for the 
pathogenesis of psoriasis. The inflammatory infiltrate is believed to be due to the 
production of large amount of cytokines by keratinocytes. The increase in 
 keratinocyte proliferation is due to T-cells as evidenced by in vitro studies. The 
cytokines cause T-cell activation which again secretes cytokines and growth factors 
leading to further proliferation of keratinocytes establishing a vicious cycle. Thus T 
cells are found to play a direct role in pathogenesis of psoriasis. Mor et al., in his 
experiments had proved T-cells synthesize and secrete VEGF. Immunostaining had 
confirmed that VEGF is a mediator in angiogenesis and epidermal hyperplasia.15 
The involvement of T-cells in psoriasis was discovered by its improvement 
with T-cell suppressive agents. T-cells are of two subtypes: CD8+ cytotoxic T-cells 
and CD4+ helper T-cells. Both these subtypes are found to be increased in psoriatic 
skin lesions.  Initially only Th-1 and Th-2 cells are identified and was thought to be 
responsible for allergies and autoimmune responses. However, in recent years, a 
complex array of phenotypes of CD4+ helper cells are described including T-reg 
(regulatory T-cell), Th 17, Th 22, and Th 9 cells. Psoriasis is now considered to be 
mainly mediated by IL-17 producing Th 17 cells. This concept is confirmed by 
success in treatment with either IL-17 targeting drugs like Secukinumab, 
Bimekizumab, and Ixelkizumab or IL-17 receptor blockers like Broadalumab.16 
Histopathology of psoriasis lesion: 
The phagocytic system of skin consists of heterogenous cells that belong to 
two cell lines. They are monocyte-macrophage and dendritic cell lines. These cells 
are specialized phagocytes playing significant roles in cleansing of apoptotic cells, 
harmful molecules and also in defense against infections. The dendritic cell lines 
include Langerhans cells and dermal dendrocytes. In psoriatic lesions, increase in 
 dermal dendritic cells and decrease in epidermal dendritic cells especially 
Langerhans cells are observed. In psoriasis these dendritic cells and Langerhans 
cells modify T cell proliferation and release of cytokines. Langerhans cells have an 
anti-inflammatory role, hence decrease in their levels in psoriasis prolongs the 
inflammatory reaction.17 
Autoimmune changes in psoriasis: 
The autoimmune changes in psoriasis are characterized by dermal 
hyperplasia and infiltration of skin by immune cells that have migrated from blood. 
The histological features seen in psoriatic skin are keratinocyte hyper-proliferation, 
dermal angiogenesis and infiltration of inflammatory cells like T lymphocytes, 
neutrophils, monocytes and macrophages. Th-1 and Th-17 cytokines are found in 
psoriatic skin, together with other interleukins like IL-17A, IL-17F, IL-19, IL-20, 
IL-22, IL-23, IL-24, IL-26 and TNF-α in serum and skin lesion. Th-17 cells are a 
subset of CD4+ T cells. Th-17 cells in addition to IL-17 also secrete IL-21, IL-22, 
IL-23. IL-17 secreted by these cells play a regulatory role in chronic inflammation 
linking beneficial and pathological effects of immune system paving way for 
autoimmunity.18 
Th1/Interferon pathway was originally implicated in this immune 
dysregulation. Now it was found out that Th-17/IL-23 pathway plays a significant 
role. IL-23 is the key cytokine that facilitates differentiation of T cells to Th-17 
cells. IL-23 stained cells are seen in psoriatic skin lesions. It is produced by 
keratinocytes and also by activated antigen-presenting cells (APCs) like Langerhans 
 cells, macrophages and dendritic cells. The IL-23 binds with the IL-23 receptor 
present on T cells and form a complex.  
This complex activates the Jak 2 and Tyk, the members of Janus family of 
kinases leading to phosphorylation of signal transducers and activation of 
transcription 3 (STAT 3). This triggers the differentiation to Th-17 cells. Th-17 
cells secrete mainly two cytokines, IL-17A and IL-17F in addition to IL-21, IL-22, 
IL-26 and interferon gamma. All these cytokines activate the cascade of 
inflammation and provoke irregular replication and maturation of cells in psoriasis. 
Thus Th17/IL-23 pathway leads to chronic inflammation. IL-17 also stimulates 
angiogenesis and tissue modeling.19 
Genetic basis of autoimmunity in psoriasis: 
Genome-wide association studies evaluated gene expression in psoriasis and 
normal skin samples and identified genes relevant to the disease mechanism. A 
meta-analysis of microarray data had shown an enhancement of genes and 
expression at high levels in keratinocytes, T-cells and innate immune cells in 
association with elevated expression of genes in psoriasis lesions. From this it is 
understood that psoriasis is an auto-immune inflammatory disease that depends on 
interactions among multiple cell types from the skin such as T-cells, dendritic cells, 
macrophages, keratinocytes together with the adaptive and or innate immune 
systems. The cells release cytokines which reinforce the inflammatory cascade 
resulting in the appearance of plaque like lesions coated with silvery scales. 
 Development of inflammatory infiltrate is a characteristic feature of psoriasis 
lesions.20 
Clinical types of psoriasis: 
Psoriasis shows a wide spectrum of cutaneous manifestations with varying 
clinical features and severity. Various forms of this dermatosis can be present at the 
same time. All the lesions of psoriasis share the common characteristics which 
include erythema and thickening with round, oval or polycyclic borders. The size of 
the lesions varies from a pinhead till 20 cm diameter. The regions frequently 
involved are knees, elbows, scalp, lumbosacral region, and genital area.  
Psoriasis is classified by its clinical appearance into 2 groups: pustular and 
non-pustular lesions. Non-pustular type includes psoriasis vulgaris, guttate 
psoriasis, erythrodermic psoriasis, palmoplantar psoriasis, inverse psoriasis, and 
psoriatic arthritis (PsA). Pustular psoriasis includes generalized pustular psoriasis 
(von Zumbusch type), localized pustular psoriasis and impetigo herpetiformis. 
1) Psoriasis vulgaris: It is the most frequent clinical form constituting 90% of 
psoriasis cases. It present as sharp bordered erythematous plaques with 
pearlescent squamae covering over it. The lesions are symmetrically 
distributed over elbows, knees, scalp, and sacral region with a probable 
predilection of trauma. Scraping of the plaque exhibit layers of white 
lamellae followed by candle wax referred as wax spot phenomenon.  Further 
scraping reveals a wet layer pathognomonic of psoriasis called last 
membrane phenomenon followed by erythematous background with 
 bleeding foci seen as small red pinpoints termed as Auspitz sign. Healed 
psoriatic plaques show a hypopigmented macular ring called Woronoff ring. 
2) Guttate psoriasis:  This type is frequently observed in children and young 
adults with sudden onset of small droplets like lesions generally following 
streptococcal infections. The lesions are seen on the scalp, face, trunk and 
proximal part of extremities. 
3) Erythrodermic psoriasis: It is a generalized form with predominant 
erythematous lesions affecting nearly 80% of body surface area. There is 
widespread vasodilatation and hypothermia.  
4) Palmoplantar psoriasis: There is symmetrical involvement of palms and 
soles with predominant squamae more frequently affecting the thenar 
regions. Erythema is not common, but if present will appear as a pinkish-
yellow lesion.  
5) Psoriatic arthritis (PsA): Arthritis can be manifested either before, during or 
more commonly after skin manifestations. It can be seen in different clinical 
forms. Moll and Wright described 5 subgroups in psoriatic arthritis.  
a) Classical type: The lesions are seen in distal interphalangeal joints of hands 
and feet with frequent nail involvement. 
b) Asymmetric oligoarticular arthritis: The most characteristic form of joint 
involvement is seen in this type. The knee joints, metacarpophalangeal, 
metatarsophalangeal, proximal and distal interphalangeal joints are 
asymmetrically affected. 
 c) Symmetric poliarticular form:  Distal interphalangeal joints are frequently 
involved in this form and may be complicated by bony ankylosis. 
d) Arthritis mutilans: This form presents with progressive osteolysis of 
phalangeal and metacarpal bones and also sacroiliitis.  
e) Spondylitic form: Isolated spondylitis is rare and generally associated with 
peripheral arthritis. Though this form resembles ankylosing spondylitis, it 
has a better prognosis due to less severe joint ankylosis. 
6) Inverse psoriasis: Lesions of this variety are localized in skin folds and 
present as bright red fissured plaques with distinct contours. This is also 
called flexural psoriasis and is common in obese individuals. 
7) Generalized pustular psoriasis: It is a rare form frequently affecting young 
individuals. It has a sudden onset with high fever, lassitude, polyarthralgia 
and an erythematous background. The disease progresses with drying and 
eruption of new pustules. 
8) Impetigo herpetiformis: This rare form is also called generalized pustular 
psoriasis of pregnancy is characterized by erythematous lesions which start 
at the flexural regions, get covered with pustules and then may agglomerate. 
The mucous membranes and skin are involved with itchy, foul smelling and 
burning sensation. There can also be deterioration of general health with 
fever, shivering, lassitude, nausea and vomiting. It is named after its 
occurrence in last trimester of pregnancy. 
 
 
 9) Localized pustular psoriasis: 
It is of 2 forms: Barber’s pustular psoriasis and acrodermatitis continua of 
Hallopeau . 
a) Barber’s pustular psoriasis: It is a chronic, recurrent form occuring 
frequently in women and accompanied with family history. Clinically 2 – 4 
mm sized pustules are observed on palmoplantar region, and especially 
erythematous on thenar and hypothenar regions.  
b) Acrodermatitis continua (Hallopeau disease): It is a proximally progressing 
skin disorder affecting fingers and toes with sterile pustular eruptions with 
sequelae of loss of nails and distal phalanges in severe cases. Pustules may 
get joined to form polycyclic, purulent, fluid-filled vesicles.  
 Clinical types of psoriasis are not a determinant of severity or progress of 
disease. It is important in treatment aspect.21 
Severity of psoriasis: 
Psoriasis is classified into mild, moderate and severe depending on 
erythema, induration and desquamation of plaques and the amount of involved body 
surface area. The classification based on body surface area is done using PASI 
(Psoriasis Area and Severity Index).22 
Most trials of psoriasis patients are restricted to most common psoriasis 
vulgaris form. The commonly used measurement in psoriasis is Psoriasis Area and 
Severity Index (PASI) which gives a quantitative assessment of burden of psoriasis 
 lesions. It is based on how much is the body surface area involved and how much is 
the degrees of severity of erythema, induration, and desquamation or scaling.  
The PASI was calculated based on following parameters: 
1. Numbers 0 to 4 is given for the degree of severity of erythema, induration 
and scales. 
2. The percentage of lesion in each area is graded as 0 to 6 as  
0 = 0%, 1 = <10%, 2 = 10–29%, 3 = 30–49%, 4 = 50–69%, 5 = 70–89%, and 
6 = 90–100%. 
3. Number assigned for the weight of each region such as  
0.1 for head and neck,  
0.2 for upper extremities,  
0.3 for body, and  
0.4 for lower extremities.23 
The formula can be made by abbreviating the prerequisites as follows 
Head -h, trunk-t, upper extremity- u, lower extremity-l 
Surface area involved – A 
Erythema – E, 
 Infiltration – I,    Desquamation – D 
  Formula for PASI is  
0.1(𝐸ℎ +  𝐼ℎ +  𝐷ℎ)𝐴ℎ +  0.2(𝐸𝑢 +  𝐼𝑢 +  𝐷𝑢)𝐴𝑢 +  0.3(𝐸𝑡 +  𝐼𝑡 +  𝐷𝑡)𝐴𝑡 
+  0.4(𝐸𝑙 +  𝐼𝑙 +  𝐷𝑙)𝐴𝑙. 
The calculated score ranges from 0-72.24 
The severity of psoriasis is classified as moderate with PASI score between 10 and 
20, severe when it was above 20.25 
Fredriksson and Pettersson developed PASI in 1978 to evaluate the clinical 
efficiency of psoriasis treatment. American Academy of Dermatology (AAD) had 
recommended the PASI score and percentage of body surface area as the measures 
to assess extent of psoriasis while planning for treatment.26 
Based on surface area of skin involvement, psoriasis is classified into three 
discrete categories: mild psoriasis affecting ≤ 2% of body surface area, moderate 
affecting 3 to 10% of body surface area and severe affecting > 10%.  
A cross sectional study by The Health Improvement Network of UK found 
out that psoriasis is associated in a dose-response fashion with metabolic syndrome 
(mild cases show a 22% increase in Odds of metabolic syndrome, 56% in moderate 
and 98% in severe psoriasis). 
 According to National Psoriasis Foundation, psoriasis globally affects more 
than 125 million people. It is the most common type 1 T helper cell inflammatory 
disease. The proinflammatory state associated with psoriasis is the dragging force 
towards development of metabolic syndrome. In these patients, Th1 inflammatory 
 cytokines like TNF-α, IL-1 and IL-6 are increased in blood and skin. Inflammatory 
mediators affect insulin signaling, lipid metabolism and adipogenesis. Inflammation 
induced IR may lead to a systemic IR state. Increase in odd’s of raised serum 
glucose and triglycerides are seen in psoriasis patients independent of obesity 
effect.27 
Psoriasis and comorbidities: 
The etiology of psoriasis remains to be identified. Evidences through 
scientific studies suggest that psoriasis is a complex disorder coordinated with the 
interplay between multiple genes. Psoriasis and its comorbidities together have a 
significant overlap in the variations of action in similar set of genes. The link 
between psoriasis and its comorbidities was coined as “diseasome”.  
Network medicine studies at Vellore Institute of Technology University have 
found out the molecular association between psoriasis and its comorbidities. The 
number of genes or proteins shared between psoriasis and T2DM were 312 of 
which 26 proteins are directly connected 210 proteins interact through partnering 
with other proteins. Similarly, the number of genes or proteins shared between 
psoriasis and MI (myocardial infarction) were 31 out of which 7 proteins are 
connected directly and 49 proteins are related indirectly.  
This study had found that the psoriasis associated comorbidities are 
interrelated at the molecular level shared by common genes in addition with the 
level of proteins, biological processes and pathways. This study had provided an 
evidence for reality of a shared component hypothesis between psoriasis and its five 
 common comorbidities for instance MI, T2DM, obesity, rheumatoid arthritis and 
Alzheimer’s disease. The study of these molecular connections not only aid in 
anticipation and management of psoriasis but also serves as a starting point for 
diagnosis and treatment of its comorbidities.28 
The complex pathology of psoriasis requires elucidation of genetic, genomic, 
proteomic and metabolic elements for its molecular definition. Davidovici et al., 
hypothesized that inflammatory products could have been synthesized in the skin 
and released by diffusion through the cutaneous endothelium into the systemic 
circulation.  The key mediators of inflammation in psoriasis are cytokines - tumor 
necrosis factor-α (TNF), interleukin – 17 (IL-17), or interferon – γ, (IFN-γ). IL-17 
and TNF have additive and synergistic effects on modulating gene expression in 
keratinocytes.  
Skin biopsy study by Mayte Suárez-Fariñas observed over expression of 
renin, cytotoxic T-lymphocyte antigen (CTLA)-4 and Toll-like receptor (TLR)-3 
genes and their protein products at higher levels in psoriasis skin. Renin gene is 
involved in rennin-angiotensin pathway leading to aldosterone release and 
vasoconstriction. The CTLA-4 gene is identified in the functional pathway of 
metabolic diseases. 
 TLR3 signaling stimulates keratinocytes, releasing more proinflammatory 
cytokines, TNF and IL-8 and also activates IFN- and TNF-stimulated gene 
products. Thus there is increased expression of inflammatory cytokines or proteins 
responsive to these cytokines with a corresponding increase in mRNA in psoriasis 
 lesions. These gene products are linked to functional pathways leading to metabolic 
diseases suggesting a potential link between altered gene transcription in psoriasis 
skin and its comorbid diseases.  
This link between psoriasis and metabolic comorbidities can be explained by 
two mechanisms. First is the hormone like proteins produced by psoriatic plaques 
for example renin and vascular endothelial growth factor. Second is the association 
of dysregulated gene expression present in psoriasis lesions with metabolic 
pathways leading to atherosclerosis, PPARα &RAR activation and leptin 
signaling.29 
Metabolic derangements in psoriasis: 
Psoriasis is characterized by local and also systemic escalation of 
proinflammatory cytokines. These proinflammatory cytokines in chronic 
inflammation are accused of augmenting the process of atherogenesis and 
peripheral insulin resistance leading to hypertension and T2DM respectively. 
Moreover recent studies showed that psoriasis is in association with other metabolic 
disorders such as dyslipidemia, abdominal obesity, insulin resistance, and even 
cardiac disorders. These findings suggest that psoriasis patients are preconditioned 
to DM, hypertension and metabolic syndrome. Of these DM is said to occur at any 
age and HT occur with higher rates as age advances.  
The prevalence of metabolic syndrome is found to be high in psoriasis 
patients particularly after the age of 40 irrespective of the severity and duration of 
psoriasis. The study of Ilkin Zindancı in Turkey concluded that psoriasis 
 predisposes to DM, hypertension, and MS and the prevalence of MS is increased by 
3-fold. Therefore they recommended evaluating psoriasis patients for MS.30 
MS also called insulin resistance syndrome or Syndrome X is a combination 
of predictors of cardiovascular disease risk. It includes central obesity, 
hypertension, glucose intolerance and dyslipidemia. A study conducted at 
Department of Dermatology, Pusan National University Hospital have found out 
that there is no statistically significant difference in MS between psoriasis and 
control group after adjusting for age and gender but the triglycerides level is higher 
(42.7%) in psoriasis when compared to controls (26.2%) with a p value of <0.001. 
Careful attention should be paid in psoriasis patients to look for dyslipidemia 
concentrating more on triglyceride levels.31 
Psoriasis and components of MS: 
The MS if present can be diagnosed on the basis of presence of≥3 criteria of 
the modified National Cholesterol Education Program's Adult Treatment Panel III 
as follows:  
waist circumference >102 cm in men or>88 cm in women, 
hypertriglyceridemia ≥150 mg/dL, 
high-density lipoprotein cholesterol <40 mg/dL in men or <50 mg/dL 
in women,  
blood pressure ≥130/ 85 mmHg and 
fasting plasma glucose ≥100 mg/dL. 
 Psoriasis is associated with significant morbidity affecting the quality of life 
even with limited body surface area involvement. Globally several studies have 
reported association between psoriasis and metabolic syndrome including obesity, 
diabetes, dyslipidemia, hypertension and recently atherosclerosis. But in India, 
there is a paucity of data on this association despite evidences suggest that Indians 
are genetically and environmentally more prone to develop metabolic syndrome. A 
cross-sectional study conducted at All India Institute of Medical Sciences, New 
Delhi had found a linear trend of increase in metabolic syndrome with increasing 
degree of severity of psoriasis in patients compared to controls. Dyslipidemia is the 
most common parameter whose values are inconsistent among various studies.32 
The pattern of dyslipidemia found in metabolic syndrome characterized with 
elevated triglycerides and low HDL cholesterol is reported to be in association with 
psoriasis. Several studies like El Asmi et al. analysis of Tunisian psoriatic group 
and Damevska et al., study have shown hypertriglyceridemia in psoriasis patients. 
The relation between psoriasis and IR is also well documented. Several studies have 
underlined a link between impaired glucose metabolism and psoriasis. An 
observational study done by Brauchli et al., has revealed an increased risk of DM in 
psoriasis patients than in psoriasis-free group.33 
 Psoriasis and dyslipidemia: 
A diagnosis of dyslipidemia can be made based on the following levels: 
triglycerides ≥150 mg/dl, or high-density lipoprotein cholesterol (HDL-C) ≤ 40 
mg/dl in men or ≤ 50 mg/dl in women. A study at Federal University of Bahia had 
 shown that dyslipidemia was associated with psoriasis even after adjusting other 
known confounding factors. 34 
Genome wide association studies (GWAS) has found out that there is a 
significant genetic overlap between dyslipidemia and immune mediated disorders. 
There is sharing of susceptibility loci between them. The genetic loci that are shared 
with triglycerides is in loci 88, with LDL is in loci 87 and with HDL is in loci 52. 
These shared loci may be associated with overlapping of the pathophysiology 
between these two conditions. Atherosclerosis itself is a chronic inflammation of 
arterial walls together with sub-endothelial accumulation of lipids. There is 
experimental evidence which supports that inflammation plays a key role in 
atherosclerotic plaque formation.35 
The proinflammatory cytokines elevated in psoriasis for example TNF IL-1 
or IL-6 affect the metabolism of lipids leading to a high frequency of dyslipidemia. 
Studies at Brazil, Japan and Israel have shown 67%, 34.3% and 56.9% respectively 
of dyslipidemia in psoriasis patients. Research at the University clinical center 
Tuzla have taken composition of lipids in dyslipidemia associated with psoriasis as 
a subject of interest and found that not only overall cholesterol is increased, more 
significantly there was hypertriglyceridemia (39%) and a lowered value of HDL 
(36%). The average age of psoriatic affected by this dyslipidemia was 48.76years.36 
Recent studies by Medical University of Graz, Austria have provided 
evidence that inflammation impairs the function of HDL and hence the reverse 
cholesterol transport. HDL is a complex lipoprotein which exerts athero-protective 
 activity by promoting cholesterol efflux from the macrophages through reverse 
cholesterol transport. This cholesterol efflux capacity is negatively correlated with 
severity of psoriasis leading to a deteriorated lipid profile with high values of LDL, 
triglycerides and low levels of HDL. Thus dyslipidemia become more frequent in 
psoriasis.37 
Psoriasis is also associated with an increased hepatic inflammation, 
potentially via the excess production of TNF-α in the skin and serum. Observations 
on animal models had shown that chronic hepatic inflammation in subclinical 
inflammatory states, such as diabetes increased the synthesis and secretion of apo-B 
containing particles (LDL and VLDL) in the liver. A study done on University of 
Pennsylvania School of Medicine hypothesized that psoriasis being a chronic 
inflammatory disease would be associated with an impaired cholesterol efflux and 
abnormal lipoprotein particles profile. Furthermore, they have demonstrated that 
HDL dysfunction and impairment of reverse cholesterol transport (RCT) will occur 
in human inflammatory syndromes contributing to increased CVD risk.38 
Psoriasis and cardiac status: 
Nehal Mehta highlighted the strong evidence of connection between 
inflammatory state, psoriasis and cardiometabolic disease. A human endotoxemic 
model study in healthy human volunteers had revealed activation of innate immune 
pathways relevant to cardiometabolic disease such as peripheral IR, endothelial cell 
activation and impaired reverse cholesterol transport and characterized by increased 
cytokine signaling. These findings suggest a shared cytokines and inflammatory 
 mechanism between psoriasis and atherosclerosis favoring cardiovascular 
pathology. The inflammatory mediators from the skin are found to access the 
systemic circulation, then reach back to act on the subcutaneous fat and distant 
tissues resulting in interference of insulin signaling contributing to a metabolic state 
that favor cardiovascular pathology.39 
A population based cohort study with UK electronic medical record data was 
the first study that evidenced an increase in cardiovascular risk in psoriasis patients. 
This is followed by many studies that reported a high risk of T2D, hypertension, 
hyperlipidemia, hypercholesterolemia and obesity. However, a cross-sectional study 
by KORA (Cooperative Health Research in the Region of Augsburg, Germany) 
showed that no statistically significant difference exists between BMI, blood 
pressure and total cholesterol to HDL cholesterol ratio. Statistically significant 
association is seen with waist circumference, T2D and MI. Thus psoriasis appears 
as an independent risk factor for T2D and MI.40 
Psoriasis and type 2 DM: 
Cohort studies at Boston had found an elevated risk of incident T2D among 
younger individuals with psoriasis.  They suggested the probable link between 
psoriasis with IR and T2D could be inflammatory cytokines such as IL-6 and TNF 
and adipokines such as leptin and adiponectin. They concluded that immune-
mediated inflammatory processes, metabolic biomarkers and environmental factors 
would form the connecting link between psoriasis and diabetes.41 
 A study on Danish population comparing the incidence rates of DM among 
normal and psoriasis patients had shown a significantly higher incidence of new 
onset DM irrespective of age and concomitant morbidity. Chronic inflammation 
associated with increase in tumor necrosis factor-α and insulin-like growth factor-II 
was found as a link between psoriasis and type 2 DM. Recent studies suggested an 
improvement of insulin sensitivity in psoriasis patients with the use of tumor 
necrosis factor-α antagonists which emphasized the overlap and sharing of disease 
mechanism between chronic inflammatory diseases and DM. Hence psoriasis 
patients are at increased risk of DM.42 
A large multicenter study on T2D patients with psoriasis had revealed that 
the patients with both the diseases are disadvantaged as they have to manage two 
diseases. Their self-care on diabetes might be neglected despite requiring intense 
therapy. Insulin therapy was more frequently needed for treatment of these patients 
probably due to the association between inflammation and insulin resistance. The 
decrease in insulin sensitivity worsens the metabolic control so such patients should 
be encouraged to concentrate on their metabolic status and improve it by life style 
changes.43 
Rahat S. Azfar had shown in his study that the risk of diabetes was increased 
amongst psoriasis patients in a dose dependent manner with the severity of illness. 
They had found psoriasis as an independent risk factor for incident diabetes.  Hence 
psoriasis patients should be encouraged to undergo therapeutic lifestyle changes to 
lower their risk of diabetes and appropriate screenings for signs of insulin 
resistance.44 
 Psoriasis and obesity: 
Psoriasis is a chronic auto-immune inflammatory skin disease expressing as 
skin plaques affecting mainly the scalp, back, elbows and knee, chronic plaque type 
being the most common form. The skin lesions of psoriasis being visible present 
early but MS has insidious changes and delayed symptoms with a high morbidity 
together with mortality. Studies of varying methodologies on association between 
these two will provide early opportunities for diagnosing and treating it.  
Most of the Indian and international studies could not show a significant 
difference in BMI between psoriasis patients and controls. The mean BMI of 
psoriasis patients and controls in a hospital based case control study by 
Praveenkumar at Pondicherry medical college were 24.23 and 24.56 respectively. 
The mean waist circumference of psoriasis patients in this study was lesser than that 
of controls. Hence, we see that obesity is not an important component for MS in 
psoriasis patients of India.45 
Insulin: 
Insulin is a beautifully organized protein discovered by Frederick Banting 
and Charles Best during the year 1921 in Toronto. Following this great discovery 
and crystallization of insulin by John Jacob Abel in 1926, various laboratory studies 
were performed. C. R. Park and coworkers established the action of insulin in 
facilitating the transport of glucose via plasma membrane in tissues such as muscle. 
Research works had provided evidence on the direct action of insulin on liver in 
increasing the glycogen content, RNA synthesis, protein synthesis and also DNA 
 synthesis after 36 to 60 hours of insulin stimulation. Further studies indicated the 
action of insulin in the expression of genes encoding metabolic pathway regulating 
enzymes including those of glycolysis and gluconeogenesis. Insulin is also known 
to stimulate many anabolic processes.46 
Secretion of insulin: 
Insulin is synthesized, stored and secreted from the beta cells of the 
pancreatic islets. Insulin biosynthesis is encoded by insulin gene and regulated at 
transcriptional and translational levels. The synthesis begins with the formation of a 
110 amino acid precursor called preproinsulin, which translocates across the rough 
endoplasmic reticulum membrane via a peptide conducting channel into the lumen. 
During this journey, the signal peptide is cleaved from preproinsulin by peptidase to 
yield proinsulin.  
The proinsulin undergoes folding, disulphide bonds formation and 
maturation of three dimensional conformation.  The proinsulin then gets transported 
to the golgi apparatus, enter the secretory vesicles and cleave to insulin and C-
peptide. This insulin together with C-peptide and islet amyloid polypeptide are 
stored in secretory granules. Fusion of these secretory granules with the plasma 
membrane results in the release of insulin into the circulation. The insulin stored in 
the β cell granules are in a hexameric form and they get dissociated to monomeric 
forms in the circulation. 2D NMR studies have revealed these different forms of 
insulin and the native structure of insulin.47 
 
 Actions of Insulin: 
Insulin is secreted from islet β cells of pancreas following food intake. 
Insulin act on insulin receptors expressed on the skeletal muscle and adipose tissue 
and stimulate the glucose uptake in these cells through GLUT4 (glucose 
transporter). This uptake of glucose by skeletal muscle and adipose tissue serves to 
maintain glucose homeostasis by very low level of glucose uptake during basal 
condition and robustly activated glucose entry following food intake in response to 
insulin. This rapid glucose clearance is through insulin responsive glucose 
transporter GLUT4. In response to insulin, intracellular GLUT4 protein vesicles 
translocate to the plasma membrane, become a membrane spanning protein and 
facilitate the uptake of glucose. The interaction of these vesicles and SNARE 
proteins located at the plasma membrane favor this effect.48 
Mechanisms of insulin action:  
Insulin binds with the insulin receptors (IR-A or IR-B) present on the cell 
membrane and activates an intrinsic tyrosine protein kinase. This leads to 
autophosphorylation of receptors and activation of insulin signaling pathways. 
Insulin signaling pathways are of two types, a dominant pathway and an alternative 
pathway. The dominant pathway contains a family of proteins called Insulin 
Receptor Substrates which activate a cascade of serine protein kinases. A major 
branch point of this pathway is by Akt (protein kinase B) and its downstream 
substrates, which are involved in various physiological functions preferably on the 
regulation of fuel homeostasis. The alternate pathway is by ras/ MAP-kinase 
 activating the serine-protein kinase cascade. This pathway plays a role in the 
regulation of transcription, protein synthesis, cell growth and differentiation.49 
Fig 1- Mechanisms of Insulin action.49 
 
 
Akt is the main mediator of most of the metabolic effects of insulin, 
regulating glucose transport, glycogen synthesis, gluconeogenesis and lipid 
synthesis. The Shc-Grb2-Sos-Ras-Raf-MAPK pathway controls cellular 
proliferation and gene transcription. 
Tyrosine phosphorylation causes activation of insulin receptors. 
Phosphorylation of serine and threonine causes shut down of insulin signal. 
Negative regulators of insulin action are cytoplasmic tyrosine phosphatases, 
transmembrane phosphatases and lipid phosphatases. The phosphatases 
dephosphorylate the tyrosine residues of insulin receptor complexes thus reducing 
their activity. This probes into the activity of rate limiting enzymes of glucose and 
 lipid metabolism such as glycogen synthase, hormone sensitive lipase and acetyl 
CoA carboxylase. Cyclic AMP and diacyl glycerol from lipids induces serine 
phosphorylation of insulin receptor complexes and impair insulin signaling.50 
Studies in Akt2 knockout mice had highlighted the essential role of Akt2 in 
GLUT4 translocation. Akt signaling associated with downstream pathways like 
mTOR was found to be responsible for skeletal muscle protein synthesis and 
enhanced glycogen synthesis.  There are evidences that mTOR activation increase 
the transport of aminoacids into the skeletal muscles. The whole body nutrient 
homeostasis is based on the nutrient handling capabilities of the skeletal muscle, 
adipose tissue and liver which are the insulin sensitive tissues.51 
Action of insulin in liver: 
In liver, insulin increases glycogen synthesis by stimulating glycogen 
synthase through Akt pathway. Insulin also suppresses glycogenolysis by 
acetylation, dephosphorylation and inactivation of glycogen phosphorylase. Insulin 
indirectly stimulates glucose uptake by stimulating the expression of glucokinase 
which phosphorylates glucose to glucose 6 phosphate. Glucose 6 phosphate is a 
precursor and an allosteric activator for glycogen synthesis and also allosterically 
inhibits glycogen phosphorylase. This can cause a further increase in liver glycogen 
levels.52 
 
 
 Insulin increases postprandial hepatic glucose utilization and suppresses 
hepatic glucose production. Insulin act on liver through direct and indirect 
pathways. The direct action is by binding with hepatic insulin receptors. 60% of 
secreted insulin is found bound with insulin receptors of hepatocytes. The 
phosphatidyl inositol 3-OH kinase pathway is activated resulting in Akt-directed 
phosphorylation of the transcription factor Forkhead box O1 (FoxO1). This causes 
termination of the transcription of two enzymes needed for gluconeogenesis, 
namely phosphoenol pyruvatecarboxykinase (PEPCK) and glucose-6-phosphatase 
(G-6-Pase).  
Experiments on mice has shown that deletion of hepatocyte insulin receptors 
has caused activation of FoxO1 leading to unregulated glucose production and 
glucose intolerance. Studies also reveal indirect or extrahepatic regulation of 
hepatic glucose production done by insulin. The proposed mechanisms are 
suppression of glucagon secretion from pancreas, inhibition of lipolysis and 
proteolysis hence there is reduced availability of gluconeogenic precursors and 
finally control via central nervous system action. Thus, liver plays an important role 
in glucose homeostasis by increasing its consumption in postprandial state and 
production in fasting state. This hepatic glucose metabolism is impaired in 
diabetes.53 
 
 
 
 Fig 2 – Metabolic role of Insulin in various organs53 
 
 
Insulin is a regulator of many metabolic functions of liver including 
cholesterol homeostasis. Insulin promotes lipogenesis, lipoprotein synthesis and 
VLDL secretion. Hence hepatic IR contribute to dyslipidemia.54 
The stimulation of denovo lipogenesis in liver by insulin is through nuclear 
hormone LXR (liver X receptor). Knock down of LXR by antisense 
oligonucleotides in mice liver has proved the interaction of insulin and LXR in the 
regulation of lipogenic genes. Induction of LXR by insulin causes activation of the 
lipogenic enzymes like fatty acid synthase and stearoyl CoA desaturase and also 
lipogenic transcription factors namely sterol regulatory element-binding protein-1c 
and carbohydrate response element-binding protein. LXR is also found to play a 
 major role in activating the synthesis of unsaturated fatty acids, facilitating 
cholesterol efflux and hence reverse cholesterol transport. When there is insulin 
resistance, the lipogenic action of LXR induced by insulin is continued but the 
cholesterol efflux is decreased leading to fatty liver and increased triglycerides in 
circulation.55 
Euglycemic hyperinsulinemic clamp technique studies in moderately obese 
individuals have explained that the lipolytic suppression effect of insulin in adipose 
tissue is by decreasing the activity of hormone sensitive lipase and adipose tissue 
triglyceride lipase resulting in decreased release of NEFA. Insulin also increases the 
triglyceride clearance by stimulating the activity of lipoprotein lipase. There is an 
acute inhibition of VLDL secretion following postprandial insulin spike.56 
Action in heart: 
 Glucose metabolism in heart is 4-fold greater in cardiac muscle than skeletal 
muscle and they show a greater expression of the major insulin-responsive glucose 
transporter, GLUT4. Insulin signaling causes translocation of GLUT4 receptors 
from the intracellular pool to the cell surface and increases glucose uptake into the 
cells. Insulin has the same action on GLUT1 of cardiomyocytes to a lesser extent. 
GLUT4 and GLUT1 receptors account for 60% and 40% of total glucose carriers, 
respectively.  
Insulin also activates the intracellular signaling proteins causing tyrosine 
phosphorylation of insulin receptor substrate (IRS), and activation of phosphatidyl-
inositol-3 kinase (PI 3-kinase), Akt/protein kinase B (PKB), and protein kinase C. 
 The maintenance of glucose metabolism in necessary for normal cardiac function 
and abnormal function and cell death can occur when the cardiac ability to utilize 
glucose is impaired.57 
IR affects cardiac function. There is decreased entry of glucose into the cell 
through GLUT-4 receptors and increase in fatty acid accumulation. There is 
increased expression of cardiac PPAR-α (peroxisome proliferator activated receptor 
alpha) resulting in enhancement of fatty acid uptake and oxidation. So the cardiac 
metabolism switches from glucose utilization to fatty acid oxidation. This in turn 
decreases cardiac efficiency. 
 Nitric oxide mediated coronary vasodilatation is also mediated by Akt 
pathway. IR in endothelial cells of heart produces impaired generation of nitric 
oxide leading to hypoxia and reduced angiogenesis. Endothelial insulin resistance 
causes an increased release of endothelin-1 (ET-1) which causes cardiac 
hypertrophy and fibrosis.58 
Insulin resistance: 
Insulin resistance is defined as disturbance in the biological action of insulin 
such as reduction in the insulin mediated glucose disposal and inhibition of hepatic 
glucose production. There is a failure in response of body cells to effectively use 
insulin. When this condition progresses, apoptosis of islets cells leads to DM. Since 
IR is a major predisposing factor in the occurrence and progression of DM, it is 
used as a screening index in the primary prevention of DM. Reaven proposed a 
model of DM progressed from IR.  
 Recent evidences have shown a non-obesity related correlation between IR 
and DM. According to WHO, IR is taken as a value greater than 75th percentile of 
that of non-diabetic subjects. HOMA-IR is found to be the most convenient and 
efficient way to measure IR using fasting plasma insulin and fasting plasma 
glucose.59 
Measurement of IR: 
IR is an independent risk factor and develops early in the pathological 
process of diabetes. There are evidences in many studies that IR predate the onset 
of the diabetes even by 10-20 years. Hence quantitative assessment of IR can be 
very useful before abnormal glucose tolerance or diabetes sets in. The quantitative 
measurement of the effect of insulin in relation to blood glucose level is termed as 
an index of insulin resistance.  
A simple index of IR is defined as an index estimated from a fasting blood 
sample with or without other blood samples following no interventions such as 
intravenous administration of exogenous glucose or insulin. Such simple indices are 
convenient and easy, hence most commonly used for estimating IR. HOMA-IR and 
QUICKI are examples of these simple indices and they are based on fasting glucose 
and insulin. They assess hepatic IR more sensitively than peripheral insulin 
sensitivity. Hepatic IR is considered the major factor contributing to fasting 
hyperglycemia, impaired fasting glucose and pre-diabetic state. Peripheral tissue IR 
tends to develop at a later stage but there is a correlation between hepatic and 
peripheral IR.60 
 QUICKI (quantitative insulin sensitivity check index) is one of the classical 
insulin resistance indices which was once found to be the most accurate and useful 
index for determining insulin sensitivity in humans. However, QUICKI and insulin 
action are not correlating in individuals with mild insulin resistance or in impaired 
glucose tolerance stage. Hence QUICKI is less robust in diagnosing IR early before 
T2DM or MS sets in. 
 IR is the root factor for T2DM. It is the most unifying parameter which 
characterizes the pathophysiology of MS.  Though MS is found to drive into T2DM 
and cardiovascular disease, T2DM is independently associated with higher risk of 
cardiovascular disease which is further aggravated by MS factors. Adiponectin and 
resistin are thought to bridge T2DM and MS with cardiovascular risk.61 
A one year follow up study on 2642 Japanese workers has found a cause-
effect relationship between IR and MS. This study evaluated the insulin related 
biomarkers such as HOMA-IR (Homeostasis Model Assessment for Insulin 
Resistance) and QUICKI (Quantitative Insulin Sensitivity Check Index). HOMA-IR 
and QUICKI are calculated as follows: 
𝐻𝑂𝑀𝐴 − 𝐼𝑅 =  (𝐹𝑃𝐺 𝑖𝑛 𝑚𝑔/𝑑𝑙 ×  𝑖𝑛𝑠𝑢𝑙𝑖𝑛 𝑖𝑛 𝑚𝐼𝑈/𝐿)/405 
𝑄𝑈𝐼𝐶𝐾𝐼 =  1/[𝑐𝑜𝑚𝑚𝑜𝑛 𝑙𝑜𝑔𝑎𝑟𝑖𝑡ℎ𝑚𝑠 (𝐹𝑃𝐺 ×  𝑖𝑛𝑠𝑢𝑙𝑖𝑛)] 
Although fasting plasma glucose is used, contributions of glucose level to these 
calculations are relatively small. WHO defines IR as HOMA-IR values ≥ 1.8, but 
for this Japanese study, HOMA-IR ≥ 2.5 is considered as a significant factor for the 
 development of MS. But this HOMA-IR and QUICKI are applicable only with 
fasting blood sugar levels less than 140 mg/dl. 62 
McLaughlin et al., has identified the lipid ratio TG/HDL-C as another means 
of identifying IR with a sensitivity 79% and specificity 85%. They proposed a cut-
off value of ≥ 3.5 as a predictor of IR.A study done at the Cardiology department of 
Medical College & Hospital, Kolkata on acute coronary syndrome patients from 
April 2011 to March 2012 have found that TG/HDL-C ratio has a higher screening 
ability and sensitivity to identify IR when compared to TC/HDL-C ratio.  
Significant association between TG/HDL-C and IR had been reported by 
Brehm et al. But recent data suggest that IR is an independent predictor of 
cardiovascular disease irrespective of hypertension, obesity or dyslipidemia. Yet, 
plasma total cholesterol, triglycerides and HDL-C were independently associated 
with insulin levels and hence IR.63 
Metabolic derangements due to IR: 
IR in several tissues such as liver, muscle, adipose tissue, vascular tissue and 
neuronal tissue can drive into hyperinsulinemia. The six major pathways that are 
disrupted in metabolic diseases (i.e. obesity, metabolic syndrome, and Type 2 
diabetes) are impaired hepatic glucose uptake and glycogen deposition, activated 
gluconeogenesis and de novo lipogenesis, accelerated fatty acid delivery and 
triglyceride esterification. 
Liver is the major organ that handles a greater proportion of dietary nutrients 
during the 24 hour feed-fast cycle. In the fasting state, IR is associated with 
 inability of insulin to restrain hepatic glucose production resulting in 
inappropriately high levels of glucose production by increase in gluconeogenesis 
and glycogenolysis. Also the insulin mediated glucose uptake in muscle cannot be 
augmented resulting in hyperglycemia. 
The liver normally switches its function following a carbohydrate meal from 
production to net consumption of glucose. It stores a substantial amount of glucose 
as glycogen which can be released in the post-absorptive state by glycogenolysis. 
The concentrations of glucose and insulin together determine the magnitude of this 
hepatic glucose uptake. But during IR, the liver fails to get switched off following a 
meal from production of glucose to its consumption. The insulin can neither 
suppress hepatic glucose production nor augment glucose uptake in the liver 
contributing to exaggerated hyperglycemia. But this IR is so selective, that there is 
augmented hepatic lipogenesis and triglyceride accumulation.  
Although glucose uptake in the brain is not generally regulated by insulin, 
specific areas in brain exhibit IR ad modify the neural circuits that regulate the 
response of liver and peripheral tissues to insulin thereby exacerbating impaired 
glucose metabolism. 
In addition, there is impaired suppression of glucagon secretion from the 
pancreas as well as adipose tissue lipolysis. These extrahepatic factors exacerbate 
the ineffectiveness of insulin to suppress hepatic glucose production and enhance 
liver glucose uptake.64 
 Insulin normally acts as an anti-lipolytic hormone in adipose tissue and it 
suppresses the release of stored fatty acids by decreasing the activity of hormone 
sensitive lipase. In conditions of IR in fat cells, higher levels of free fatty acids 
leave the fat cells and reach the circulation to be taken up by liver and skeletal 
muscles which cannot safely store large amounts of fat. There is a paradoxical 
activation of lipoprotein lipase in hyperinsulinemia which hydrolyzes lipoprotein 
triglycerides at the surface of fat cells to release free fatty acids. The excess fat 
released into the blood stream and sequestered by other organs mark the beginning 
of lipotoxicity. The progress of chronic diseases associated with IR becomes 
accelerated with increased lipotoxicity. Thus IR has to be categorized as a 
metabolic dysfunction and keeping insulin within a therapeutic zone is vital for 
survival.65 
Inflammation and IR: 
There is a potential role of inflammatory cells in mediating IR. Studies had 
demonstrated role of macrophages, CD4 and CD8 lymphocytes in developing IR. 
The cytokines secreted by the T cells directly impair the action of insulin in target 
tissues. In vitro studies had shown evidences that increase in interleukin-6 (IL-6) 
and tumor necrosis factor-α (TNF-α) could induce IR. Tracey McLaughlin in his 
studies had concluded that CD4 cells, CD8 cells and T-helper cells are highly 
associated with systemic inflammation and IR. 66 
Inflammation is a mechanism of defense that protects and also helps to 
recover the body from infections or any insults. The relative balances between 
 proinflammatory and anti-inflammatory immune cells have a tight control over the 
process of inflammation. Dysregulation of inflammation had been implicated as a 
major cause of many autoimmune diseases. In vitro studies have shown that pro-
inflammatory cytokine TNFα lowers the level of insulin signaling components, 
induce the phosphorylation and hence inhibition of IRS thereby inhibits insulin 
signaling.  
The linear signaling cascade following insulin binding to its receptor and 
resulting in Akt activation is disrupted in insulin resistance. This impairment 
chiefly affects the insulin responsive cells such as adipocytes, myocytes, 
hepatocytes and β-cells interfering with the translocation of GLUT4 and synthesis 
of glycogen. Adipose tissue and muscle are similarly affected where IR present as 
inability of glucose disposal. This is compensated by secretion of more insulin by 
pancreatic β-cells. However the β-cells fail when the limit of their secretory 
capacity is crossed. The inappropriately low level secretion of insulin in response to 
a definite concentration of glucose leads to T2D.67 
IR and diabetes: 
Diabetes itself is a group of metabolic diseases having high blood sugar 
values either due to insufficiency of insulin production or impairment in biological 
response to insulin, the second one being considered as IR. T2DM is characterized 
by IR and hyperglycemia. IR is considered as the salient feature of T2DM. IR also 
contribute to beta cell failure evidenced by observing apoptosis of beta cells 
following elevated glucose concentrations in cultured islet cells from diabetes-
 prone Psammomys obesus. There are evidences that insulin is uniquely secreted by 
beta-cells and has anti-apoptotic role via PI3K/Akt pathway thereby protecting the 
beta cells. The beta cell mass is maintained by a dynamic process of balance in 
replication and apoptosis. In IR, beta cell failure sets in.  
 Blood glucose homeostasis is crucially maintained by the arrival and 
localization of GLUT4 in the plasma membrane of muscle and adipose tissue with 
subsequent cellular glucose influx. This normal metabolic process of glucose 
uptake in skeletal muscle and adipose tissue are impaired in IR. Thus IR had 
become the initiating mechanism in the pathogenesis of T2DM consequently 
leading to glucose toxicity.68 
Diabetes is the final stage of the pathogenic process that start as IR with 
increased strain on beta cells of pancreas, progressing through prediabetes stage  
with impaired ability to control blood sugar and reaching into full blown diabetes 
with death of beta cells and inability to control fluctuations of blood sugar with 
natural insulin. IR is compensated for a time period by its increased production by 
putting considerable strain on beta cells. By the time diabetes occur, 80% of beta 
cells were lost. IR along with its predisposition to diabetes is also associated with 
early cardiovascular morbidity and other complications. So at the stage of 
prediabetes itself, untreated patients will be entering into the very high risk of full-
blown diabetes, cardiovascular events and other complications.  
 
 
 ADA had proposed diagnostic criteria for prediabetes as follows: 
Impaired glucose tolerance - as 140 to 200 mg/dL 2-hour post load glucose level 
following oral glucose tolerance test (OGTT), 
Impaired fasting glucose - as 100 to 125 mg/dL of fasting glucose levels orA1C 
(glycated hemogloblin) level at 5.7% to 6.4%.  
The above criteria can only identify prediabetes, the stage of inability to control 
blood sugar within normal limits exercising beta cells to IR. Thus though the above 
tests are cheaper, there is a great need for diagnostic tests to identify early signs of 
IR. The battle against diabetes can be won only by identifying and aggressively 
treating the root cause IR.69 
Maintenance of glucose tolerance within normal physiological limits by 
complex feedback mechanism is called glucose homeostasis.  The direct measures 
of glucose homeostasis are euglycemic clamp and frequently sampled intravenous 
glucose tolerance test. Their indirect measures are fasting insulin and fasting 
glucose. These measures indicate IR and β cell response.  
Aberrant glucose homeostasis contributes to IR, where there is inappropriate 
use of insulin by muscle, fat and liver. Hence more insulin is required for the use of 
same amount of glucose. But as IR goes on increasing, the circulatory levels of 
glucose will also shoot up resulting in hyperglycemia contributing to T2DM.When 
insulin secreting capacity is decreased, established T2DM had set in. So the 
secretory capacity cannot be used as a predictor of T2DM and increased IR is taken 
 into account as measures of β cell function in prediabetic subjects. This concept is 
termed as Disposition Index.70 
 
Disposition Index is the product of acute insulin response and insulin 
sensitivity following an intravenous glucose tolerance test.  In vitro studies in 
mouse and human islet cells  have revealed that elevated circulating free fatty acids 
suppress the expression of transcription factors in β cells. So there is an impaired 
ability of β cells to sense glucose and secrete appropriate insulin. Thus the ability of 
β cells to compensate for low insulin sensitivity is impeded. This β cells 
compensation of IR can be measured using Disposition Index.71 
International Obesity Task Force criteria for Asian populations has defined 
obesity and overweight as ≥25 kg/m2 and ≥23 kg/m2 respectively. Impaired Glucose 
Tolerance (IGT) and T2DM are associated with increase in insulin resistance (IR). 
 T2DM is the result of beta cell exhaustion following IR. The pancreas compensates 
to increasing IR until beta cell failure supervenes. IR was also said to be related to 
body fat.72 
India possess a major contribution to the global health burden in diabetes 
The World Health Organization (WHO) and International Diabetes Federation 
(IDF) have reported a prevalence rates of diabetes is between 2.8% and 5.1% in 
individuals ≥20 years of age. In India, the National Urban Diabetes Survey 
conducted at six major cities, revealed 12% prevalence rates of diabetes and 14% 
impaired glucose tolerance. With an increase in population size and rate of disease 
India is expected to have an estimated prevalence of 80 million diabetics by 2030, 
and this accounts for one-fifth of world diabetics.  
 Asian Indians have a higher risk of Type 2 diabetes and premature coronary 
artery disease when compared to Europeans. This is related to a higher frequency of 
hyperinsulinemia, insulin resistance, dyslipidemia specially low HDL cholesterol  
and increased visceral fat, the features collectively referred to as the ‘Asian Indian 
Phenotype or Paradox’. 
 Epidemiologic studies also show a strong role for genetics as evidenced by 
an increased risk for Type 2 diabetes and impaired glucose tolerance (IGT) in 
persons with positive family history. The etiology of Type 2 diabetes though not yet 
fully understood, it is likely that genes and environmental components play a major 
role in pathophysiology.73 
 Statistics reveal that India is expected to have 79.4 million people with 
diabetes by 2030 and carry the largest cardiovascular disease burden of the world. 
There is an increased prevalence of diabetes in South India specially a consistent 
escalation in younger population from 25.0 to 35.7% during the period of 2000 to 
2007. These people are relatively low in birth weight and have hyperinsulinemia 
together with higher concentration of nonesterified fatty acids during fasting.74 
IR and dyslipidemia:  
Indians are relatively more Insulin Resistant probably due to the higher 
abdominal obesity. Adipocytokines are synthesized and secreted by adipocytes, 
they include adiponectin, resistin, leptin, TNF-α and IL-6. These factors play an 
important role in development of IR. IR is compensated by hyperinsulinemia. 
Hyperinsulinemia accelerates hepatic VLDL synthesis contributing to increased 
triglyceride levels. Also hyperinsulinemia stimulate sympathetic nervous system, 
proliferation of smooth muscle cells of blood vessels and increases sodium 
absorption contributing to hypertension.75 
Studies done at Chinese and Flemish people have found that insulin 
resistance increased with increase in triglycerides and decrease in high density 
lipoprotein. The studies were conducted in association with Helsinke Declaration 
for investigation. IR was computed by HOMA-IR, also by C-peptide in diabetics 
and by insulin in non-diabetics. LDL cholesterol was calculated via Friedewald 
formula using serum HDL, triglycerides and total cholesterol. They found a close 
relation between lipoprotein metabolism, circulating level of triglycerides and HDL 
 cholesterol and it is disturbed in diabetic and IR patients.  Dyslipidemia and 
inflammation are chaperones to IR. Their study implies that lowering of serum 
triglycerides, increasing HDL levels and controlling inflammation should be the 
main targets for prevention or treatment of IR.76 
Gerald Reaven (Stanford, CA) had discussed the interrelation among 
hyperinsulinemia, hypertension, and cardiovascular disease. Reaven had found 
association of IR with elevated levels of BMI, fasting glucose, insulin, and 
triglyceride levels and low HDL cholesterol levels in a study on Italian population 
and hence he suggested that people with insulin resistance are in the group who has 
all the cardiovascular risk factors. This IR lipid pattern of elevated triglycerides and 
low HDL cholesterol was associated with increased CVD risk.77 
IR and cardiac status: 
IR is associated with impaired fibrinolysis characterized by 
hypercoagulability with elevation of fibrinogen and plasminogen activator inhibitor 
(PAI)-1. Hence IR becomes a prothrombotic state leading to a higher risk of 
cardiovascular events.78 
Insulin increases fatty acid uptake by the heart but inhibits its utilization for 
energy. Insulin stimulates the uptake and oxidation of glucose by the cardiac 
muscle. Therefore insulin resistance causes a reduction in energy supply to the 
myocardium and a change in substrate utilization from glucose towards fatty acids. 
Thus IR become a central part of MS, the pathophysiology being associated with 
pro-inflammatory, prothrombotic and oxidative state predisposing to atherosclerotic 
 cardiovascular disease. The data of EPIPorto cohort study, Portugal showed that 
diastolic dysfunction of the heart deteriorates with IR and it predicts the future 
onset of heart failure.79 
IR and MS: 
MS is nothing but the constellation of factors including impaired glucose 
tolerance, low high density lipoproteins and high triglycerides predisposing the 
individual to increased risk of diabetes and cardiovascular illness. It has a complex 
pathogenesis and helps as a useful tool to identify the people who are at increased 
risk of diabetes and coronary illness. Ramchandran et al., has reported a 41% 
prevalence of MS in urban area of Chennai on the basis of modified ATP-III 
criteria. Prevalence of MS is found to be high among Indians. 80 
The term MS refers to a group of conditions including obesity, 
hyperlipidemia, high blood pressure and IR. MS can present in different forms but 
IR is suspected to form a common pathophysiological link between MS and its 
etiological components. The risk of developing all the abnormalities of MS is found 
to be strongly associated with IR.81 
The health problems type 2 diabetes (T2D), and cardiovascular diseases 
(CVDs) are often preceded by the abnormalities such as obesity, insulin resistance, 
impaired glucose tolerance, dyslipidemia and high blood pressure together 
collectively called as MS. The abnormalities that are usually estimated for the 
diagnosis of MS include central obesity, triglycerides, high-density lipoprotein and 
fasting plasma glucose. Though the pathophysiology of MS is complex, majority of 
 patients had IR. MS not only leads to a high risk of type 2 diabetes, coronary or 
peripheral atherosclerosis and cardiovascular disease but also associated with some 
other systemic complications such as fatty liver disease, respiratory disease, and 
cancer.82 
IR is a characteristic finding in MS. The progression of IR to T2DM happens 
only with exhaustion of beta cells. But the other compensations for 
hyperinsulinemia progresses before T2DM appear. A study on South Asians and 
Europeans had found a clear trend of higher IR in the order starting from no MS/ no 
T2DM, MS/ no T2DM to MS/ T2DM supporting their assessment that many people 
with IR may not develop T2DM. Their study also showed that South Asians are 
more vulnerable to chronic diseases such as MS and T2DM as they are predisposed 
to IR, dyslipidemia and beta-cell dysfunction at an earlier age.83 
A SMART study at Netherlands used HOMA-IR to quantify IR to 
investigate the association of IR with occurrence of metabolic disturbances and 
cardiovascular abnormalities. HOMA-IR was taken for quantitative estimation of 
degree of IR. The extent to which HOMA-IR is related to each component of MS 
was evaluated in relation to ATP III criteria.  
 
 
 
 The relation between IR and components of MS based on this study is as 
follows: 
 
MS components IR 
0 1.4 ± 0.7 
1 1.8 ± 1.2 
2 2.4 ± 1.5 
3 3.1 ± 1.8 
4 4.0 ± 2.6 
5 5.6 ± 3.6 
 
ATPIII criteria defined MS as having 3 of the metabolic abnormalities. They had 
found that IR is a major driver underlying the pathophysiology of MS and 
associated with increased cardiovascular risk and mortality.84  
HOMA-IR is a surrogate method for estimating IR in epidemiologic or 
clinical setting. The cut-off values of HOMA-IR vary according to ethnicity and 
metabolic conditions of populations studied and defined by percentiles criteria. The 
optimal cut-off values of HOMA-IR to take into account as MS as per ATPIII range 
from 2.07 at 50 years and 2.47 at 70 years. The optimal cut-off suggested by IDF 
for MS was 2.05. In Spain, the threshold had dropped from 3.46 to 2.05 considering 
MS components.85 
 Various studies have taken value of HOMA-IR as 2.5 to indicate IR in 
adults. The same value is also found to provide maximum sensitivity and specificity 
in diagnosing MS in adolescence of both genders as per ATP III and IDF criteria.86 
Psoriasis and IR: 
Psoriasis is a T- cell mediated disease having increased Th type1 
proinflammatory cytokines performing wide range of actions on insulin signaling, 
lipid metabolism and adipogenesis. Several studies had found a high risk of 
diabetes in psoriasis patients with IR as the probable link. IR was found even in 
non-obese patients and said to be in correlation with psoriasis index severity area. 
The inflammatory mediators involved in IR are disturbed in psoriasis. The 
inflammatory molecules produced in psoriasis skin including TNF, VEGF, 
interferon-γ and interleukins are released into the circulation depending on the 
severity and extent of skin lesion.87 
A significant decrease in HOMA-IR was seen with a decrease in PASI. A 
prospective cohort study at Turkey had found IR in psoriasis patients, but their 
sample size is less taking 35 patients, hence the difference in IR found between 
patients and controls were not statistically significant. But the adipokine levels of 
psoriasis patients were similar to that of in prediabetic individuals supporting the 
association with IR. 88 
Psoriasis is associated with increased oxidative stress with decreased 
antioxidant capacity. The systemic inflammatory burden in psoriasis contributes to 
 IR. IR results in a state of shifted equilibrium of balanced proatherogenic and 
antiatherogenic effects towards predominant proatherogenic effects.89 
The pathology of MS could be characterized by peripheral insulin resistance. 
MS is associated with IR and according to a study by Wilson et al., MS promotes 
the occurrence of T2D. Studies by Shoelson et al., Kalupahana et al., and Stienstra 
et al., have revealed a strong relationship between chronic low-grade inflammation 
and insulin resistance where pro-inflammatory cytokines such as interleukin-1β, 
interleukin-6 play a connecting role.  It has been recognized that a pro-
inflammatory state contributes to disease development and progression. In support 
of such a relationship is the observation that metabolic and immune response 
pathways are evolutionarily integrated and partly overlapping, and it is clear that 
the immune system plays a role in the development of metabolic diseases.  
There is a close link between inflammation and metabolic disease, but the 
responsible mechanisms remain elusive. Skeletal muscles account for the major part 
of insulin induced glucose uptake but there is ignorance regarding the link between 
inflammation and IR in skeletal muscle. A closer examination had revealed 
presence of upregulated inflammatory genes such as histone deacetylase 9 
(HDAC9), interleukin 6 receptor (IL6R) and CD97 molecule (CD97) in skeletal 
muscles which might play an important role in development of IR.90 
Balato N and colleagues hypothesized in their study that the inflammatory 
mediators of autoimmune reactions in psoriatic march caused IR and this 
contributed to comorbidities such as diabetes and hypertension. Their data 
 confirmed this association. Also their findings supported the synergistic effects of 
chronic inflammations due to obesity and psoriasis, the concept put forward by 
Hamminga et al .91 
Based on recent advances, it was found that both psoriasis and 
atherosclerosis are characterized by acceleration of immunological activity of 
helper T cells of type 1 and represent an ongoing systemic inflammatory state. 
Studies are now pointing towards IR as playing a primary role in forming a 
common association. This holds true even for psoriasis of mild severity and is 
independent of obesity. Insulin resistance state is proposed to be diminished by 
therapeutic interventions with methotrexate and tumor necrosis factor α 
antagonists.92 
Thus though psoriasis is considered a chronic, T-cell mediated inflammatory 
disease chiefly affecting the skin and joints, several observational studies have 
demonstrated an association between psoriasis and systemic disorders eventually 
linked by elevated cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-
α (TNF-α). So there are recommendations to upgrade psoriasis to a systemic 
disease.93 
Psoriasis is also a risk factor for development of abdominal obesity, 
hypertension and dyslipidemia. The inflammation pathogenic to psoriasis also 
develops atherosclerotic and metabolic disorders and vice versa. So a dermatologist 
is also responsible for diagnosing and monitoring these concomitant disorders. A 
 study had revealed that there is no difference in prevalence of insulin resistance and 
abnormalities of lipids between psoriatic patients and Polish citizens.94 
Asians have a higher predisposition to obesity, MS, DM and cardiovascular 
disorders when compared to western population. There is a scarcity of literature 
highlighting the association of psoriasis with these morbidities. Comorbidities are 
multigenic, multifactorial timely unrelated secondary diseases involving same or 
other organs. This occurs in psoriasis. A higher prevalence of MS is seen in Indians 
and psoriasis represents an additional route for morbidity due to its positive 
correlation with IR. A study conducted at Department of Dermatology, Topiwala 
National Medical College and B.Y.L Nair Charitable Hospital, Mumbai have found 
a significant association between psoriasis and diabetes with odd’s ratio 2.63 of 
abnormal glucose homeostasis in psoriasis. But IR did not appear to be related to 
duration or severity of psoriasis. They had suggested that further studies have to be 
carried out using large sample size.95 
The prevalence of comorbidities in psoriasis is relatively low, hence large 
sample sizes are required to attain sufficient power in testing the associations. The 
observational studies can generate hypotheses, but cannot easily generate results 
that differentiate clearly between association and causality. The likelihood of a 
causal relation increases when a clear biological explanation is found for the 
association, confirmed by multiple studies with a dose-response relationship 
between exposure and outcome. The increased inflammatory status in psoriasis 
patients associated with higher levels of the multifunctional cytokine tumor necrosis 
 factor-α is proposed as the biological explanation found in association between 
psoriasis and several comorbidities.96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MATERIALS AND METHODS 
SOURCES OF DATA 
 Psoriasis patients who attended the skin outpatient department of Sree 
Mookambika Institute of Medical Sciences, Kulasekharam, Tamilnadu and healthy 
age matched controls formed the subjects for the present comparative study. A total 
of 200 subjects which included 100 psoriasis patients and 100 normal persons, who 
came to the hospital during the time period of April 2016 to March 2017 were 
enrolled in the study. 
INCLUSION CRITERIA 
(1) All patients diagnosed with psoriasis attending skin outpatient 
department of Sree Mookambika Institute of Medical Sciences during the study 
period. 
(2) Age between 18 to 60 years. 
(3) Bystanders of patients attending various departments of Sree 
Mookambika Institute of Medical Sciences were taken for comparison.  
EXCLUSION CRITERIA 
(1) Patients with the following ailments were excluded: 
Known diabetic patients,  
Patients with known cardiovascular disease,  
  Patients with known chronic kidney disease,  
Severely ill patients,  
Patients taking systemic steroids or cyclosporine. 
(2) Subjects not willing to participate. 
METHOD OF COLLECTION OF DATA 
 Informed consents were obtained from the subjects after explaining about the 
study. The data was collected using a prestructured proforma. Baseline data 
including age, gender, occupation, detailed medical history including number of 
relapses, clinical examinations and relevant investigations were included as part of 
methodology.  
 The following parameters were collected: age, gender, blood pressure, 
height, weight and biochemical parameters. Blood pressure was recorded in sitting 
position in the left arm using the mercury sphygmomanometer (Diamond Deluxe 
BP apparatus, Pune, India). Two readings were taken 5 minutes apart and the mean 
of the two were taken as blood pressure. The standing height and weight were 
measured using stadiometer and digital weigh scale respectively. The Body Mass 
Index (BMI) was calculated as the weight of the body in kilograms to the square of 
the height in meters. 
Body mass index = Weight (Kg) / Height {m2} 
 Blood samples (5 ml) were collected employing standard infection 
prevention procedures from each participant after an overnight fasting of 12 hours.  
2ml of blood was transferred to a fluoride vacutainer for fasting plasma glucose 
estimation and 3 ml of blood was transferred to a vacutainer containing clot 
activator. The serum was separated by centrifuging the blood in clot activator tube 
at 2500 rpm for 10 minutes. The plasma was separated by centrifuging the blood in 
fluoride vacutainer at 3500 rpm for 15 minutes. The samples were then used to 
determine the concentration of glucose, HDL cholesterol, triglyceride, and serum 
insulin. 
1. ESTIMATION OF INSULIN 
 Serum insulin level was estimated by immuno-enzymatic sandwich assay 
using Beckman Coulter Access 2 Immunoassay Systems 
PRINCIPLE  
 The Access Ultrasensitive Insulin assay is an immuno-enzymatic sandwich 
assay. The serum sample is added to a reaction vessel along with mouse 
monoclonal anti-insulin alkaline phosphate conjugate and paramagnetic particles 
coated with mouse monoclonal anti-insulin antibody.97After incubation, the bound 
materials are held in a magnetic field and the unbound materials are washed away. 
Then the chemiluminescent substrate Lumi-Phos 530 is added to the vessel and the 
light generated by the reaction is measured with a luminometer. The intensity of 
 light production is proportional to the concentration of insulin in the sample. The 
amount of analyte is determined from a multipoint calibration curve. 
REAGENTS 
Reagent 1a 
Mouse monoclonal anti-insulin coupled to 
paramagnetic particles, TRIS buffer,                        
bovine serum albumin matrix. 
Reagent 1 b 
Mouse monoclonal anti-insulin conjugated to bovine 
alkaline phosphatase, TRIS buffer, BSA matrix. 
Reagent 1 c Mouse IgG in HEPES buffer, BSA matrix. 
 
PROCEDURE 
  The assay was done using Beckman Coulter Access 2. The reagent packs 
were loaded in the instrument. 20 µL of sample was used up for each assay. The 
results in µIU/mLwere displayed at the appropriate screen. 
REFERENCE RANGE 
Normal Range Units 
1.9-23 
13.0-161 
µIU/mL 
pmol/L 
 
 2. ESTIMATION OF BLOOD GLUCOSE 
Blood glucose was estimated by hexokinase glucose-6-phosphate 
dehydrogenase method. 
PRINCIPLE 
Glucose is phosphorylated to glucose-6-phosphate by hexokinase enzyme in 
the presence of adenosine tri phosphate and magnesium ions. Glucose-6-phosphate 
is oxidized to 6-phosphogluconate by glucose-6-phosphate dehydrogenase. During 
this reaction NAD+ (nicotinamide adenine dinucleotide) is reduced to NADH 
(reduced nicotinamide adenine dinucleotide). The change in absorbance measured 
at 340/380 nm is proportional to the amount of glucose in the sample. 
REAGENTS 
Reagents Concentration 
PIPES- buffer (pH7.6) 
NAD+ 
Hexokinase 
ATP 
Mg2+ 
G6P-DH 
24.0 mmol/L 
≥ 1.32 mmol/L 
             ≥ 0.59 KU/L 
             ≥ 2 mmol/L 
              2.37 mmol/L 
            ≥1.58 KU/L 
 
 
 PROCEDURE 
 After making entry of patient details, the sample of plasma was introduced 
into Beckman Coulter AU 480. The results displayed were recorded in mg/dl. The 
values can be multiplied by 0.0555 for mmol/L.  
REFERENCE VALUE 
Adult 
70 – 105 mg/dL 
3.  CALCULATION OF INSULIN RESISTANCE 
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) defines 
Insulin Resistance. HOMA-IR was calculated using the fasting plasma glucose 
levels and fasting serum insulin levels. The product of fasting plasma glucose in 
mg/dl and fasting serum insulin in mIU/L is divided by 405 to obtain the values of 
HOMA-IR. 
HOMA-IR = (FPG in mg/dl × insulin in mIU/L)/405 
The HOMA-IR values equal to or greater than 2.5 is taken as IR.98 
4.  ESTIMATION OF SERUM TRIGLYCERIDES 
PRINCIPLE 
The triglycerides present in the serum are hydrolyzed by lipases to glycerol 
and fatty acids. Glycerol is phosphorylated to glycerol -3-phosphate by adenosine 
tri phosphate in the presence of glycerol kinase. The glycerol -3-phosphate is then 
 oxidized to form hydrogen peroxide and dihydroxyacetone phosphate in the 
presence of glycerol phosphate oxidase. The hydrogen peroxide formed reacts with 
4-aminophenazone and N,N-bis-3,5-dimethylaniline, disodium salt (MADB) in the 
presence of peroxidase and produce a chromophore which is read at 660/800nm. 
The increase in absorbance is proportional to the triglyceride content of the sample. 
REAGENTS 
PIPES buffer (pH 7.5) 
Lipase (Pseudomonas) 
Glycerol kinase 
Glycerol phosphate oxidase 
Ascorbate oxidase  
Peroxidase  
ATP 
4-Aminoantipyrine 
Magnesium acetate  
MADB 
50 mmol/L 
≥ 1.5 kU/L (25 μkat/L) 
≥ 0.5 kU/L (8.3 μkat/L) 
≥ 1.5 kU/L (25 μkat/L) 
≥ 1.5 kU/L (25 μkat/L) 
≥ 0.98 kU/L (16.3 μkat/L) 
1.4mmol/L 
0.50mmol/L 
4.6 mmol/L 
0.25mmol/L 
 
 
 PROCEDURE 
 After making data entry, the sample was introduced into Beckman Coulter 
AU 480. The result displayed at the appropriate screen is registered. 
 
REFERENCE RANGE 
Serum Triglyceride Risk Classification 
<150 mg/dL 
150-199 mg/dL 
200-499 mg/dL 
≥500 mg/dL 
Normal 
Borderline High 
High 
Very High 
 
4.  ESTIMATION OF HIGH DENSITY LIPOPROTEINS 
Selective measurement of HDL cholesterol was done using two reagent 
homogenous system. 
PRINCIPLE 
 The assay of HDL cholesterol is composed of two distinct phases. In phase 
1, cholesterol present in non-HDL-lipoproteins are solubilized by cholesterol 
oxidase, peroxidase and DSBmt (N,N-bis-m-toluidine disodium) to generate a 
 colorless product.  In phase 2, an unique detergent selectively solubilizes HDL-
lipoproteins. The HDL cholesterol released react with cholesterol esterase, 
cholesterol oxidase and a chromogen system to yield a blue colored complex which 
is measured bichromatically at 600/700nm. The increase in absorbance is 
proportional to the HDL concentration in the sample.     
REAGENTS 
Goods Buffer (pH 6.0) 
Cholesterol esterase (Pseudomonas)  
Cholesterol oxidase (E.coli)  
Peroxidase (Horseradish)  
Ascorbate oxidase (Curcubita sp,) 
DSBmT 
4-aminoantipyrine 
 
375 U/L 
750 U//L 
975U/L 
2250U/L 
0.75mmol/L 
0.25mmol/L 
 
REFERENCE VALUES 
Adults 23-92 mg/dl 
A value of less than 40 mg/dL is indicative of a major risk factor for coronary heart 
disease. 
 STATISTICAL ANALYSIS 
 Data collected were entered in the excel sheet. Analysis was done by SPSS 
version 20. Percentage, mean and standard deviation were calculated. Independent 
sample “t” tests were done for comparison of variables in two groups. The p values 
of < 0.05 were considered as statistically significant. 
  
 RESULTS 
 
The present study was undertaken to evaluate the presence of insulin 
resistance in psoriasis patients and the association of alterations in parameters like 
fasting plasma glucose, serum high density lipoproteins and serum triglycerides in 
these patients. The study population was 200, of which 100 are psoriatic patients 
and 100 are healthy age matched controls. 
GENERAL CHARACTERISTICS OF THE STUDY POPULATION 
 
Age: 
                                                          Table 5.1 
Group Age Mean S.D 
Control Male 46.8 9.4 
Control Female 43.52 11.1 
Study Male 47.3 9.9 
Study Female 43.4 11.3 
  
Table 5.1 gives the mean age for males and females in the control group and 
study group. The mean age for males in the control group is 46.8 years with a 
standard deviation of 9.4 and the mean age in the study group is 47.3 years with a 
standard deviation of 9.9. The mean age for females in the control group is 43.52 
years with a standard deviation of 11.1 and the mean age in the study group is 
43.4years with a standard deviation of 11.3. 
 Figure 5.1 
 
Gender: 
The sex wise distribution among controls and patients are as follows:  
Table 5.2 
Gender Control group Study group 
Male 54% 55% 
Female 46% 45% 
 
Table 5.2 gives the sex wise distribution among the control group and study group. 
54% of males and 46% of females were under control group and 55% of males and 
45% of females were included in the study group. 
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Distribution of different parameters: 
Table 5.3 
Parameters Group  Mean Std. Deviation P value 
BMI 
Control group 23.35 1.07 
0.008 
Study group 24.06 2.46 
AGE 
Control group 45.34 10.32 
0.872 
Study group 45.58 10.73 
FPG 
Control group 91.68 5.86 
<0.0001 
Study group 96.53 8.73 
INSULIN 
Control group 8.04 1.82 
0.001 
Study group 10.85 7.99 
HDL 
Control group 47.84 7.61 
<0.0001 
Study group 40.72 7.03 
TG 
Control group 111.63 21.52 
<0.0001 
Study group 146.78 49.64 
HOMA-IR 
Control group 1.82 0.43 
<0.0001 
Study group 2.62 2.03 
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  Table 5.3 shows the mean and standard deviation of different parameters 
between the control group and study group. The mean BMI of the control group is 
23.35 kg/m2 and of the study group is 24.06 kg/m2. The mean BMI of the study 
group is greater than that of the control group with a P value of 0.008. The mean 
age of the control group is 45.34 and of the study group is 45.58 having a P value of 
0.872. Hence the age factor shows no significance.  
 The mean fasting plasma glucose of the control group is 91.68 mg/dl with a 
standard deviation of 5.86. The mean fasting plasma glucose of the study group is 
96.53 mg/dl with a standard deviation of 8.73. Thus the mean fasting plasma 
glucose of the study group is higher than that of the control group with a P value of 
< 0.0001. 
 The mean serum insulin level of the control group is 8.04 μIU/ml with a 
standard deviation of 1.82. The mean serum insulin level of the study group is 
10.85 μIU/ml with a standard deviation of 7.99. The mean serum insulin level of 
the study group is greater than the control group with a P value of 0.001.  
 The mean HDL level of the control group is 47.84 mg/dl with a standard 
deviation of 7.61. The mean HDL level of the study group is 40.72 mg/dl with a 
standard deviation of 7.03. Thus the mean HDL level of the study group is lower 
than that of the control group with a P value of <0.0001. 
 The mean triglyceride level of the control group is 111.63 mg/dl with a 
standard deviation of 21.52. The mean triglyceride level of the study group is 
146.78 mg/dl with a standard deviation of 49.64. Thus the mean triglyceride level 
 of the study group is greater than that of the control group with a P value of 
<0.0001. 
 The mean HOMA-IR value of the control group is 1.82 with a standard 
deviation of 0.43. The mean HOMA-IR value of the study group is 2.62 with a 
standard deviation of 2.03. Thus the mean HOMA-IR value of the study group is 
greater than that of the control group with a P value of <0.0001.        
Comparison of BMI between control group and study group: 
 
Figure 5.3 
 
 
The average BMI for control group is 23.35 kg/m2 and for study group is 24.06 
kg/m2. 
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 Comparison of fasting plasma glucose between control group and study group: 
Figure 5.4 
 
The average fasting plasma glucose of control group is 91.68 mg/dl and of study 
group is 96.53mg/dl. 
 
Comparison of serum insulin level between control group and study group: 
Figure 5.5 
 
The average insulin level in control group is 8.04  μIU/ml and in study group is 
10.85  μIU/ml. 
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 Comparison of serum HDL between control group and study group: 
                                                         Figure 5.6 
 
The average serum HDL of control group is 47.84 mg/dl and of study group is 
40.72 mg/dl. 
Comparison of triglycerides between control group and study group: 
Figure 5.7 
 
The average serum triglyceride level of control group is 111.63 mg/dl and of study 
group is 146.78 mg/dl.  
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 Comparison of HOMA-IR values between control group and study group: 
Figure 5.8 
 
The average HOMA-IR of the control group is 1.82 and of study group is2.62. 
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 Discussion: 
 Psoriasis is associated with significant morbidity and systemic 
manifestations. The association of variety of medical conditions in psoriasis may be 
based on sharing of common risk factors and pathophysiology.99The present study 
was carried out to find the association between psoriasis and insulin resistance. The 
associated biochemical parameters fasting serum insulin, fasting plasma glucose, 
serum high density lipoproteins and serum triglycerides were estimated. The level 
of insulin resistance was calculated using HOMA-IR.  
The average fasting serum insulin in psoriasis patients was 10.85 μIU/ml and 
found significantly higher than that of the control group (8.04 μIU/ml). The high 
serum insulin levels indicate the feasibility of insulin resistance in psoriasis 
patients. Similar statistical significance was also noted by Uysal S and colleagues. 
The possible mechanism could be due to the release of adipokines and cytokines in 
psoriasis patients that impair the insulin sensitivity. The serum insulin levels 
become high in these patients. The higher concentration of serum insulin levels 
correlated positively with the disease activity.100 
The average fasting plasma glucose of our study group was 96.53 mg/dl and 
of control group was 91.68 mg/dl. The study group shows a statistically significant 
higher level of fasting plasma glucose on comparing with controls. The high fasting 
glucose levels were also reported in non diabetic psoriasis patients by Baeta IG and 
colleagues. 101There was no statistical difference in fasting plasma glucose between 
 psoriasis cases and controls in an epidemiological study at Bangalore by Gopal 
MG.102 
The level of insulin resistance in our study showed a value of 2.62 in 
psoriasis patients which is found to be significantly higher than the value 1.82 of 
the control group. The high serum insulin and insulin resistance correlated with 
several studies including a cross sectional study at Burdwan. Krishnamoorthy and 
coworkers had reported a HOMA-IR value of 3.5 in psoriasis patients and 1.4 in 
controls which supports our study. Boehncke et al., had also noted signs of IR in 
psoriasis patients.  
 The possible mechanism behind this association between psoriasis and IR 
could be due to inflammatory cytokines. There is an overproduction of cytokines in 
psoriasis patients for example tumour necrosis factor alpha which play important 
roles in the pathways that regulate insulin sensitivity. Their varied actions on 
pathways include impairment of insulin signaling by inhibition of tyrosine kinase 
activity of insulin receptor, activation of peroxisome proliferator activated receptor 
(PPAR) which modulates glucose metabolism and by suppression of adiponectin 
secretion from adipocytes, all factors contribute to IR.103 
In the present study, the average serum HDL in psoriasis patients was 
40.72mg/dl and in control group was 47.84 mg/dl. The serum HDL levels were 
found significantly low in psoriasis patients than controls. The average serum 
triglyceride value in psoriasis patients was 146.78 mg/dl and in control group was 
111.63 mg/dl. The serum triglyceride values in psoriasis patients were significantly 
 higher than that of controls. This statistically significant difference in HDL and 
triglyceride levels was also noted in a case control study by Taheri Sarvtin M and 
colleagues. The abnormality in plasma lipid mechanism occurs in psoriasis and it is 
probably related to alterations in insulin sensitivity and secretion.104 
In conditions of IR, there is increased oxidation of free fatty acids in serum 
which provides substrate for triglyceride synthesis in liver and hence the hepatic 
release of triglyceride rich VLDL into the serum is increased. The lipid profile is 
thus altered leading to increased triglycerides and decrease in HDL-cholesterol 
fraction.105 
There are much more evidences that psoriasis is associated with unfavorable 
lipid profile and enhanced atherosclerosis. The atherogenic trend in the lipid levels 
of psoriatic patients demonstrated by significantly high triglyceride and low HDL 
levels were also reported by Akkara Veetil BM and colleagues. So it is likely that 
psoriasis predispose the individuals to dyslipidemia.106 
 The average BMI calculated for psoriasis patients was 24.06 kg/m2 and that 
of the control group was 23.35 kg/m2showing a statistically significant difference 
between patients and controls. These values correlated with the findings of 
Armstrong AW and colleagues which showed a slightly increased risk of 
developing obesity in psoriasis patients when compared to controls. The precise 
mechanism of association between psoriasis and obesity was unknown. Research 
studies suggested that activation of inflammatory macrophages cause stimulation of 
adipose tissue to secrete adipokines. The coexistence of psoriasis and obesity could 
 be attributed to the action of adipokines. In addition to genetic and immune 
mediated mechanisms, behavioral factors such as reluctance to engage in physical 
activities might play an important role in connecting psoriasis and obesity.107 
 There are many studies in various regions including India evaluating 
psoriasis patients during the path of the disease process. Our study had included 
patients who were not on systemic treatment. Systemic medications for psoriasis are 
considered as independent risk factors for metabolic abnormalities in psoriasis 
patients. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 Conclusion: 
 The present study was done to estimate the level of insulin resistance and to 
study the associated biochemical parameters such as fasting plasma glucose, serum 
high density lipoproteins and triglycerides in psoriasis patients who attended the 
Outpatient Department of Dermatology, Sree Mookambika Institute of Medical 
Sciences, Kulasekharam. 
Psoriasis is a chronic autoimmune inflammatory skin disease with a genetic 
background. The inflammatory mediators that are increased in psoriasis are 
supposed to interfere with the various functions of insulin and predispose to IR. As 
expected the IR was found significantly high in psoriasis patients. 
 The main finding in the present study was significantly high level of serum 
insulin in psoriasis patients. The other findings of the study were increased insulin 
resistance, low HDL and high triglyceride levels in these patients. IR provokes 
lipolysis and release of free fatty acids into the circulation which provide substrate 
for triglyceride synthesis and the hepatic release of triglyceride rich VLDL into the 
serum is increased. The lipid profile is thus altered leading to increased 
triglycerides and decrease in HDL-cholesterol fraction. 
The insulin resistance and lipid derangements predispose the individuals to 
the risk of atherosclerosis and cardiovascular disorders. There is impairment of 
reverse cholesterol transport and augmentation in the process of atherosclerosis. IR 
also causes a reduction in energy supply to the myocardium and a change in 
 substrate utilization from glucose towards fatty acids.  The hypercoagulable, 
prothrombotic and oxidative state predispose to cardiovascular disease. 
 Thus we see that psoriasis is no longer a skin disease, rather it has 
implications over vital organ systems of the human body. It should always be kept 
in mind that skin disorders may give a clue to the existence of internal 
abnormalities. Numerous studies have also evidenced that cutaneous changes may 
be a manifestation of internal illness. There should be an expanding attention in 
psoriasis patients beyond skin pathology to rule out systemic abnormalities. 
Knowledge in depth about the biochemical basis of the association will help to 
develop substantial modifications in the early diagnosis and management of the 
internal consequences of psoriasis. The screening for insulin resistance in psoriasis 
patients provide a great opportunity to alert and motivate for proper dietary and 
weight maintenance together with life style changes.  
      
 
 
 
 
 
 
 Summary  
Psoraisis is an autoimmune skin disease influenced by genetic and 
environmental factors. Psoriasis is predisposed to various comorbidities such as 
diabetes, hypertension, atherosclerosis and cardiovascular disease due to the 
underlying autoimmune etiology. The autoimmune etiopathogenesis associated with 
increase in interleukins and TNF α form a connective link between psoriasis and IR.  
 IR is defined as a lack in the normal physiological effects of insulin on 
target tissues. IR will lead to impaired glucose tolerance state and finally T2DM. 
The metabolic consequences of increased insulin level or hyperinsulinemia have 
profound effects on lipid metabolism leading to decreased HDL and high 
triglyceride levels. This altered lipid parameters will predispose the patients to 
atherosclerosis and cardiovascular illness.  
The present study was conducted to find out serum insulin levels in psoriasis 
patients. Insulin resistance was calculated and found to be significantly higher in 
patients. Fasting blood sugar, serum HDL and triglycerides were the other 
parameters estimated and significant difference was noted in these parameters 
between patients and controls. There was a statistical difference in BMI between 
patients and controls.  IR calculated in our study had crossed the upper limit of 
normal.  
Hence the results of the present study suggested that reducing IR by a 
multidisciplinary approach can protect the patient from metabolic alterations that 
predispose to T2DM and cardiac illness. 
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